Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)
1. Mosliciguat received orphan drug designation in Japan for PH-ILD treatment. 2. Orphan designation offers priority review and up to 10 years market exclusivity. 3. Phase 2 clinical trial for mosliciguat is actively ongoing. 4. Elevated cGMP levels from mosliciguat may improve pulmonary hypertension symptoms. 5. Roivant's strategic portfolio includes mosliciguat aimed at serious diseases.